This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Canvaxin, onamelatucel-L
Description: Canvaxin is a whole-cell vaccine that contains live but irradiated cells from three melanoma cell lines. These three cell lines express multiple antigens that are associated with melanoma and other solid tumors. Administration of Canvaxin stimulates the body's immune system to produce cancer-fighting T cells and antibodies.
Amgen and Micromet
CancerVax and Serono announced on 12/16/04 a worldwide collaboration for the development and commercialization of Canvaxin. Under the Agreement, CancerVax and Serono will jointly develop Canvaxin for melanoma, as well as other indications. The companies will share equally the costs of developing Canvaxin and seeking regulatory approvals for Canvaxin.
Micromet (CancerVax) and Serono
CancerVax and Serono will co-promote Canvaxin in the U.S. and share certain expenses and profits on a 50/50 basis. Outside the U.S., Serono will have the exclusive right to commercialize Canvaxin and will pay royalties to CancerVax based on its sales of the product. Initially, CancerVax will manufacture Canvaxin for supply throughout the world. Serono may eventually establish a second manufacturing site for Canvaxin, to supply primarily markets outside the U.S.
CancerVax will receive an initial cash payment of $37 million, comprised of $25 million in upfront...See full deal structure in Biomedtracker
Partners: Merck KGaA
Additional information available to subscribers only: